Skip to main content
Premium Trial:

Request an Annual Quote

GIS, Sengenics Partner on Biomarkers for Early Detection of Cancer

NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and Sengenics said today that they have formed a partnership to identify and validate auto-antibody signatures for the early detection of cancers.

The collaboration will use protein microarray technology from Senegenics' strategic partner, Oxford Gene Technology, and will focus initially on gastric and breast cancers.

As part of the partnership, Sengenics will establish its research biomarker discovery facility at GIS this year. The goal, noted GIS Executive Director Ng Huck Hui in a statement, is to combine the antibody biomarkers discovered via the collaboration with GIS's existing proprietary genomic data to "potentially develop a new range of powerful oncology prognostic tests specific to the Singaporean population."

According to Sengenics Commercial Director Johan Poole-Johnson, the partners anticipate completing the first phase of the project within 12 months.

Financial and other terms of the agreement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.